Newnham et al. BMC Cancer 2011, 11:93 http://www.biomedcentral.com/1471-2407/11/93 Acknowledgements The authors would like to acknowledge the assistance of Michael Krypuy from the Department of Pathology, Peter MacCallum Cancer Centre in undertaking high resolution melting analysis for KRAS mutations. Funding for this project was received from The University of Melbourne (scholarship for Dr G Newnham), the Australasian Society of Cardiac and Thoracic Surgeons Foundation, and The National Health and Medical Research Council of Australia. Author details 1Department of Oncology, St Vincent’s Hospital, (Victoria Pde), Melbourne, (3065), Australia. 2Department of Respiratory Medicine, St Vincent’s Hospital, (Victoria Pde), Melbourne, (3065), Australia. 3Department of Pathology, Peter MacCallum Cancer Centre, (St Andrews Place), East Melbourne, (3002), Australia. 4Department of Anatomical Pathology, St Vincent’s Hospital, (Victoria Pde), Melbourne, (3065), Australia. 5Bioinformatics Core Facility, Peter MacCallum Cancer Centre, (St Andrews Place), East Melbourne, (3002), Australia. 6Department of Thoracic Surgery, St Vincent’s Hospital, (Victoria Pde), Melbourne, (3065), Australia. 7Centre for Genomics and Predictive Medicine, Peter MacCallum Cancer Centre, (St Andrews Place), East Melbourne, (3002), Australia. 8Department of Medicine, St Vincent’s Hospital, The University of Melbourne, (Tin Alley), Melbourne, (3010), Australia. 9Department of Pathology, The University of Melbourne, (Tin Alley), Melbourne, (3010), Australia. Authors’ contributions GN performed DNA and RNA extraction and transcriptional microarray studies, and drafted the manuscript. MC, SM and GW participated in the design of the study and co-ordinated collection of clinical data. AD performed and supervised mutation analyses. HD performed mutational analyses. JL and NT performed statistical analysis. KO performed pathology review. DT and MC conceived the idea of the study. DT supervised molecular studies and assisted in the preparation of the manuscript. All authors read and approved the final copy of the manuscript. Competing interests The authors declare that they have no competing interests. Received: 23 August 2010 Accepted: 7 March 2011 Published: 7 March 2011 References 1. Maione P, et al: Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. Oncologist 2006, 11:274-84, 3. 2. Morgan T, et al: Molecular profiling of Giant Cell Tumour of Bone and Osteoclastic Localization of Ligand for Receptor Activator of Nuclear Factor kB. American Journal of Pathology 2005, 167:117-28. 3. Weiss MM, et al: Genomic alterations in primary gastric adenocarcinomas correlate with clinicopathological characteristics and survival. Cell Oncol 2004, 26:307-17, 5-6. 4. Krypuy M, et al: High resolution melting for mutation scanning of TP53 exons 5-8. BMC Cancer 2007, 7, 168 PMID 17764544. 5. Krypuy M, et al: High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer 2006, 6, 295 PMID 17184525. 6. Smyth G: Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Statistical applications in genetics and molecular biology 2004, Article 3. 7. Smyth G, et al: The use of with-in array replicate spots for assessing expression in microarray experiments. Bioinformatics 2005, 2067. 8. Olshen A, et al: Circular binary segmentation for the analysis of array- based DNA copy number data. Biostatistics 2004, 5:557-72. 9. Petersen I, et al: Patterns of chromosomal imbalances in adenocarcinoma and squamous cell carcinoma of the lung. Cancer Res 1997, 57:2331-5, 12. 10. Bjorkqvist A, et al: DNA gains in 3q occur frequently in squamous cell carcinoma of the lung, but not in adenocarcinoma. Genes Chromosomes Cancer 1998, 22:79-82, 1. Page 10 of 11 11. Pei J, et al: Genomic imbalances in human lung adenocarcinomas and squamous cell carcinomas. Genes Chromosomes Cancer 2001, 31:282-87, 3. 12. Massion P, et al: Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridisation: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res 2002, 62:3636-40, 13. 13. Massion P, et al: Early involvement of the phosphatidylinositol 3-kinase/ Akt pathway in lung cancer progression. Am J Respir Crit Care Med 2004, 170:1088-94, 10. 14. Kim T, et al: Genome-wide screening of genomic alterations and their clinicopathologic implications in non-small cell lung cancers. Clin Cancer Res 2005, 11:8235-42, 23. 15. Tonon G, et al: High-resolution genomic profiles of human lung cancer. Proc Nat Ac Science USA 2005, 9625-30. 16. Garnis C, et al: High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH. Int J Cancer 2006, 118:1556-64. 17. Graff J, Zimmer S: Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clinical and Experimental Metastasis 2003, 20:265-73. 18. Bilanges B, Stokoe D: Mechanisms of translational deregulation in human tumors and therapeutic intervention strategies. Oncogene 2007, 5973-5990. 19. Sahin AA, et al: Flow cytometric analysis of the DNA content of non- small cell lung cancer. Ploidy as a significant prognostic indicator in squamous cell carcinoma of the lung. Cancer 1990, 65:530-7, 3. 20. Granone P, et al: DNA flow cytometric analysis in patients with operable non-small cell lung carcinoma. Eur J Cardiothorac Surg 1993, 7:351-5, 7. 21. Kasprzyk M, et al: Prognostic value of DNA ploidy: 5-year follow-up of patients with resectable squamous cell carcinoma (SCC) of the lung. Lung Cancer 2006, 51:201-6, 2. 22. Choi H, et al: Differential expression of p53 gene family members p63 and p73 in head and neck squamous tumorigenesis. Human Pathology 2002, 33:158-64, 2. 23. Barbieri C, Barton C, Pietenpol J: Delta Np63 alpha expression is regulated by the phosphoinositide 3-kinase pathway. The journal of biological chemistry 2003, 51:51408-14. 24. Glickman J, et al: Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders. Human Pathology 2001, 32:1157-65, 11. 25. Di Como C, et al: p63 expression profiles in human normal and tumour tissues. Clin Cancer Res 2002, 8:494-501, 2. 26. Pruneri G, et al: p63 in laryngeal squamous cell carcinoma: evidence for a role of TA-p63 down-regulation in tumorigenesis and lack of prognostic implications of p63 immunoreactivity. Lab Invest 2002, 82:1327-34, 10. 27. Massion P, et al: Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res 2003, 63:7113-21, 21. 28. Au N, et al: P63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol 2004, 12:240-47, 3. 29. Van Cutsem E, Nowacki M, Lang I: Randomized phase III study of irinotecan and 5FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer: The CRYSTAL trial. J Clin Pathol 2007, 25, 164s abstr 4000. 30. Thurfjell N, et al: Complex p63 mRNA isoform expression patterns in squamous cell carcinoma of the head and neck. Int J Oncol 2004, 25:27-35, 1. 31. Nylander K, et al: Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol 2002, 198:417-27, 4. 32. De Young MP, et al: Tumor-specific p73 up-regulation mediates p63 dependence in squamous cell carcinoma. Cancer Res 2006, 66:9362-8, 19. 33. Ebert E, et al: Expression of cysteine protease inhibitors stefin A, stefin B, and cystatin C in human lung tumor tissue. Adv Exp Med Biol 1997, 421:259-65. 34. Werle B, et al: Cystatins in non-small cell lung cancer: tissue levels, localization and relation to prognosis. Oncol Rep 2006, 16:647-55, 4. 35. Scagliotti GV, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with